Endocrine Abstracts

Objectives: Graves’ disease (GD) is characterized by variable disease severity at diagnosis and variable disease activity during follow-up. Antithyroid drugs (ATD) such as carbimazole (CMZ), methimazole or propylthiouracil are the first-line treatment. Current guidelines recommend a range of ATD starting dose according to GD severity, followed by dose titration until euthyroidism is reached and a maintenance dose for a specific patient is established. As thyroid hormones ...